LONDON--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, and NHS England today announced the availability of the easy ...
Dexcom has been abuzz this year amid the European approval—and submission for FDA approval in the U.S.—for its next-generation G7 continuous glucose monitoring system, which promises more accurate ...
Time in range is a powerful metric for modern diabetes management - but a new survey finds less than half of people with insulin-treated diabetes are even using it.1 A recent UK survey found that ...
The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users. Taylor Leamey wrote about all things wellness for CNET, specializing in ...
Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q4 CY2025, with sales up 13.1% year on ...
LONDON--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in continuous glucose monitoring for people with diabetes, today announced the UK launch of its Time in Range Campaign, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results